| Variable | Overall, N = 26,5391 | *Clinically Relevant Postoperative Pancreatic Fistula | p-value2 | |
|---|---|---|---|---|
| CR-POPF, N = 4,5101 | No CR-POPF, N = 22,0291 | |||
| ISGPS Criteria | <0.001 | |||
| Biochemical Leak | 385 (1.5%) | 0 (0%) | 385 (1.7%) | |
| ISGPS Grade B | 4,271 (16%) | 4,271 (95%) | 0 (0%) | |
| ISGPS Grade C | 239 (0.9%) | 239 (5.3%) | 0 (0%) | |
| No Fistula | 21,644 (82%) | 0 (0%) | 21,644 (98%) | |
| Age | 65.00 (56.00, 73.00) | 64.00 (55.00, 71.00) | 66.00 (57.00, 73.00) | <0.001 |
| Sex | <0.001 | |||
| female | 13,138 (50%) | 2,009 (45%) | 11,129 (51%) | |
| male | 13,401 (50%) | 2,501 (55%) | 10,900 (49%) | |
| BMI | 26.92 (23.56, 31.01) | 28.28 (24.67, 32.61) | 26.62 (23.33, 30.68) | <0.001 |
| Race | 0.001 | |||
| Black | 2,261 (9.7%) | 314 (8.2%) | 1,947 (10%) | |
| Other | 1,240 (5.3%) | 218 (5.7%) | 1,022 (5.3%) | |
| White | 19,691 (85%) | 3,313 (86%) | 16,378 (85%) | |
| Unknown | 3,347 | 665 | 2,682 | |
| Gland Texture | <0.001 | |||
| Hard | 6,400 (39%) | 566 (20%) | 5,834 (43%) | |
| Intermediate | 1,923 (12%) | 264 (9.4%) | 1,659 (12%) | |
| Soft | 8,194 (50%) | 1,983 (70%) | 6,211 (45%) | |
| Unknown | 10,022 | 1,697 | 8,325 | |
| Pancreatic Duct Diameter | <0.001 | |||
| <3 mm | 5,540 (35%) | 1,281 (49%) | 4,259 (33%) | |
| >6 mm | 2,582 (16%) | 248 (9.4%) | 2,334 (18%) | |
| 3-6 mm | 7,584 (48%) | 1,096 (42%) | 6,488 (50%) | |
| Unknown | 10,833 | 1,885 | 8,948 | |
| Diabetes | 6,847 (26%) | 961 (21%) | 5,886 (27%) | <0.001 |
| Preop Chemotherapy | 4,348 (16%) | 436 (9.7%) | 3,912 (18%) | <0.001 |
| Unknown | 74 | 10 | 64 | |
| Preop Radiation | 1,699 (6.4%) | 131 (2.9%) | 1,568 (7.1%) | <0.001 |
| Unknown | 93 | 10 | 83 | |
| Pathology | ||||
| Ampullary carcinoma | 1,252 (7.1%) | 311 (11%) | 941 (6.3%) | |
| Cystadenocarcinoma | 20 (0.1%) | 3 (0.1%) | 17 (0.1%) | |
| Distal cholangiocarcinoma | 476 (2.7%) | 134 (4.7%) | 342 (2.3%) | |
| Duodenal carcinoma | 522 (3.0%) | 136 (4.8%) | 386 (2.6%) | |
| IPMN-invasive | 553 (3.1%) | 70 (2.5%) | 483 (3.3%) | |
| Neuroendocrine-functioning | 667 (3.8%) | 160 (5.7%) | 507 (3.4%) | |
| Neuroendocrine-nonfunctioning | 2,317 (13%) | 525 (19%) | 1,792 (12%) | |
| Pancreatic adenocarcinoma | 11,875 (67%) | 1,487 (53%) | 10,388 (70%) | |
| Unknown | 8,857 | 1,684 | 7,173 | |
| ASA Classification | 0.033 | |||
| I-II | 6,562 (25%) | 1,171 (26%) | 5,391 (25%) | |
| III-IV | 19,939 (75%) | 3,329 (74%) | 16,610 (75%) | |
| Unknown | 38 | 10 | 28 | |
| Mortality | 337 (1.3%) | 85 (1.9%) | 252 (1.1%) | <0.001 |
| Preop Bilirubin | 9.00 (4.00, 19.00) | 9.00 (4.00, 19.00) | 9.00 (4.00, 19.00) | 0.83 |
| Unknown | 2,178 | 404 | 1,774 | |
| Serious Complication | 6,365 (24%) | 2,567 (57%) | 3,798 (17%) | <0.001 |
| Any Complication | 7,376 (28%) | 2,726 (60%) | 4,650 (21%) | <0.001 |
|
1
Statistics presented: n (%); Median (IQR)
2
Statistical tests performed: chi-square test of independence; Wilcoxon rank-sum test
|
||||